GAITHERSBURG, Md., Jan. 11, 2017 /PRNewswire/ -- GenVec, Inc.
(NASDAQ: GNVC), a clinical-stage gene delivery company, announced
today that its chief scientific officer, Douglas E. Brough, will present a talk entitled
"AdenoVerse™ platform for translational development of
innovative gene and cell therapies" during the Biotech Showcase at
the upcoming Phacilitate Cell & Gene Therapy World 2017
Conference in Miami,
Florida. Dr. Brough's presentation will highlight the utility
of the AdenoVerse technology platform for gene editing and cell
therapy approaches as well as its potential to facilitate other
gene-delivery based therapeutics and vaccines from the laboratory
bench into the clinic. Dr. Brough's presentation is scheduled
for Wednesday, January 18, 2017 at
10:50 a.m. EST; and the slides will
be posted at http://www.genvec.com/media/presentations.
About GenVec
GenVec is a clinical-stage gene delivery company focused on
developing a pipeline of cutting-edge therapeutics and vaccines
using its proprietary AdenoVerse platform. The company is a pioneer
in the design, testing and manufacture of adenoviral-based product
candidates that can deliver on the promise of gene-based medicine.
GenVec's lead product candidate, CGF166, is licensed to Novartis
and is currently in a Phase 1/2 clinical study for the treatment of
hearing loss and balance disorders. In addition to its internal and
partnered pipeline, the company is also focused on opportunities to
license its proprietary technology platform, including vectors and
production cell lines, for the development and manufacture of
therapeutics and vaccines to the biopharmaceutical industry.
Additional information about GenVec is available at www.genvec.com
and in the company's various filings with the Securities and
Exchange Commission.
Contact:
Rena Cohen
(240) 632-5501
ir@genvec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genvec-to-present-at-phacilitate-cell--gene-therapy-world-2017-300389025.html
SOURCE GenVec, Inc.